Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

udy, concluding that bavituximab has demonstrated acceptable safety and a predictable PK profile and that a maximum tolerated dose was not reached even at the highest planned dose level. The majority of adverse events reported were mild or moderate in nature.

"The quality of the results generated to date in each of our three ongoing Phase II bavituximab cancer trials is very promising," said Steven W. King, president and CEO of Peregrine. "Our oral presentation today at ASCO exemplifies the heightened interest the bavituximab cancer program is receiving from both clinical researchers and potential partners, and we look forward to reporting on progress and additional results from all three of our Phase II bavituximab studies over the rest of the year."

About Phosphatidylserine (PS)-Targeting Therapies

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Realty Trust, Inc.,(NYSE: BMR ) today announced the ... property in Seattle, Washington. A wholly owned subsidiary of ... diabetes care, has,agreed to lease 36,900 square feet, anchoring ... market., Commenting on the project, Don Foster, Corporate ...
... Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: Live ... address above., ...
... NicOx,S.A. (Euronext Paris: COX) today reported financial results for the ... third quarter of 2008:, - Positive top-line results from the ... three co-primary efficacy endpoints at week-13 (p naproxcinod ... non-inferiority to naproxen 500 mg bid at week-13 and ...
Cached Biology Technology:BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk 2BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk 3Webcast Alert: Transgenomic Inc. Announces Third Quarter 2008 Earnings Release Conference Call Webcast 2NicOx Reports Results for the First Three Quarters of 2008 2NicOx Reports Results for the First Three Quarters of 2008 3NicOx Reports Results for the First Three Quarters of 2008 4NicOx Reports Results for the First Three Quarters of 2008 5NicOx Reports Results for the First Three Quarters of 2008 6NicOx Reports Results for the First Three Quarters of 2008 7NicOx Reports Results for the First Three Quarters of 2008 8NicOx Reports Results for the First Three Quarters of 2008 9NicOx Reports Results for the First Three Quarters of 2008 10
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... O R I M M E D I A ... E CELL TRANSPLANTATION,The Regenerative Medicine Journal Stem cells derived ... animal models of lung disease Tampa, Fla. (Aug. 24, ... Transplantation (20:6), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , highlight the ...
... 1.3 million). That is a new, estimated total number ... offered -- with 6.5 million species found on land and ... the ocean depths. Announced today by Census of Marine ... analytical technique that dramatically narrows the range of previous estimates. ...
... CHAMPAIGN, Ill. A new physics-based theory could give ... of liquids composed of large polymers. This advance provides ... fast-flow, high-stress processing conditions for plastics and other polymeric ... Margaret H. Professor of materials science and engineering at ...
Cached Biology News:Stem cells derived from human amniotic fluid hold promise 2Stem cells derived from human amniotic fluid hold promise 3How many species on Earth? 8.7 million 2How many species on Earth? 8.7 million 3How many species on Earth? 8.7 million 4How many species on Earth? 8.7 million 5New theory may shed light on dynamics of large-polymer liquids 2
...
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: